Literature DB >> 16636236

Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study.

M Mazighi1, R Tanasescu, X Ducrocq, E Vicaut, S Bracard, E Houdart, F Woimant.   

Abstract

BACKGROUND: Symptomatic intracranial atherothrombotic stenoses (ICAS) are associated with high rates of cerebrovascular ischemic events.
OBJECTIVE: To conduct a prospective multicenter study to evaluate the natural history of ICAS and, in those patients refractory to medical treatment, the outcomes associated with intracranial angioplasty.
METHODS: Patients aged 18 to 80 were enrolled with symptoms attributed to a single ICAS of > or =50%. Optimal medical therapy of vascular risk factors and preventive antithrombotic therapy were at the discretion of the local investigator. Patients were eligible for intracranial angioplasty after experiencing recurrent stroke despite medical therapy. Neurologic and ultrasonographic examinations were performed at study inclusion, 3 months after enrollment, and every 6 months of follow-up thereafter, for 36 months.
RESULTS: One hundred two patients were included, with a mean age of 63.3 +/- 10.4 years. Intracranial artery stenoses involved the vertebral artery in 22.5%, the basilar artery in 25.5%, the middle cerebral artery in 26.5%, and the internal carotid artery in 25.5%. In 27.4% of the patients, the stenoses had clinical hemodynamic characteristics. During a mean follow-up of 23.4 months, 38.2% of the patients had a cerebrovascular event: ischemic stroke in 13.7% and TIA in 24.5%. Among patients with a hemodynamically significant stenosis, 60.7% had a recurrent stroke or TIA in the territory of the stenotic artery; this association was significant in univariate analysis. Twenty-eight patients underwent an endovascular procedure with a neurologic periprocedural complication rate of 14.2%. The overall vascular death rate was 8.8%.
CONCLUSIONS: Despite medical treatment, the 2-year recurrence rate of ischemic events in the territory of the stenotic artery was 38.2%. Cardiovascular events occurred in 18.6% of patients. Clinically significant hemodynamic stenoses were associated with stroke recurrence and may help identify a high risk subset of patients.

Entities:  

Mesh:

Year:  2006        PMID: 16636236     DOI: 10.1212/01.wnl.0000208404.94585.b2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  79 in total

Review 1.  Symptomatic intracranial arterial disease: incidence, natural history, diagnosis, and management.

Authors:  Ananth K Vellimana; Andria L Ford; Jin-Moo Lee; Colin P Derdeyn; Gregory J Zipfel
Journal:  Neurosurg Focus       Date:  2011-06       Impact factor: 4.047

2.  The challenges of intracranial atherosclerotic disease.

Authors:  Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2008-04

Review 3.  [Endovascular treatment for intracranial stenoses. A common statement by neurologists and neuroradiologists].

Authors:  J Berkefeld; G F Hamann; R du Mesnil; W Kurre; H Steinmetz; F E Zanella; M Sitzer
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

4.  Endovascular therapy of symptomatic intracranial stenosis in patients with impaired regional cerebral blood flow or failure of medical therapy.

Authors:  V Puetz; G Gahn; U Becker; D Mucha; A Mueller; N U Weir; B Wiedemann; R von Kummer
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

5.  Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?

Authors:  Helmi L Lutsep; Michael J Lynn; George A Cotsonis; Colin P Derdeyn; Tanya N Turan; David Fiorella; L Scott Janis; Bethany F Lane; Jean Montgomery; Marc I Chimowitz
Journal:  Stroke       Date:  2015-09-17       Impact factor: 7.914

Review 6.  Current strategies for the treatment of intracranial atherosclerotic internal carotid artery stenosis.

Authors:  Toral R Patel; Ketan R Bulsara
Journal:  Neurosurg Rev       Date:  2008-09-26       Impact factor: 3.042

7.  Routine clinical evaluation of cerebrovascular reserve capacity using carbogen in patients with intracranial stenosis.

Authors:  Manus J Donahue; Lindsey M Dethrage; Carlos C Faraco; Lori C Jordan; Paul Clemmons; Robert Singer; J Mocco; Yu Shyr; Aditi Desai; Anne O'Duffy; Derek Riebau; Lisa Hermann; John Connors; Howard Kirshner; Megan K Strother
Journal:  Stroke       Date:  2014-06-17       Impact factor: 7.914

8.  Normalization of cerebral vasoreactivity using BOLD MRI after intravascular stenting.

Authors:  Arnaud Attyé; Marjorie Villien; Florence Tahon; Jan Warnking; Olivier Detante; Alexandre Krainik
Journal:  Hum Brain Mapp       Date:  2013-02-21       Impact factor: 5.038

9.  Combination aspirin and clopidogrel for secondary prevention of ischemic stroke.

Authors:  Thalia S Field; Makoto Nakajima; Oscar R Benavente
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

10.  Advances in imaging of intracranial atherosclerotic disease and implications for treatment.

Authors:  Fan Z Caprio; Shyam Prabhakaran
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.